NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022.
“This quarter, we have continued to execute on our clinical and corporate strategy, taking the necessary steps to achieve our upcoming catalysts for the remainder of this year,” said Kristi Jones, Chief Executive Officer. “We remain on track to provide a clinical update for the NEXI-001 trial in AML during the second half of 2022, and to provide an update on the expansion cohort in the NEXI-002 trial in relapsed / refractory multiple myeloma. We also plan to file our first solid tumor IND application for HPV-associated malignancies in the near term. In parallel, we are advancing IND-enabling work for our AIM injectable modality and expect to provide updates on preclinical data for oncology and autoimmune indications throughout the second half of the year. With our new target discovery collaborations, we are well-positioned to leverage our modular AIM platform for efficient and rapid new product development. Overall, I am excited with our progress and focus on execution to deliver on upcoming catalysts.”
First Quarter 2022 Clinical and Business Highlights
Clinical and Preclinical Updates
NEXI-001
NEXI-002
NEXI-003
Injectable AIM nanoparticle programs and other preclinical research
Business Updates
Select 1Q 2022 Financial Highlights
Cash, cash equivalents and marketable securities for the Company as of March 31, 2022 were $65.0 million compared to $81.8 million for quarter ending December 31, 2021. Based upon current operating plans, NexImmune expects that its existing cash, cash equivalents and marketable securities will enable the Company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Research and development expenses were $10.4 million in the first quarter of 2022, compared to $6.0 million for the same period in the prior year. The increase in R&D expenses was mainly attributable to costs for the two clinical trials, as well as personnel-related expenses driven by increased headcount.
General and administrative expenses were $4.6 million, compared to $4.1 million for the same period the prior year. The increase was due primarily to personnel-related expenses and fees related to professional and consulting services.
Net loss, according to generally accepted accounting principles in the U.S. (GAAP), was $15.0 million for the quarter, or a basic and diluted GAAP loss per share of $0.66. This compared to a net loss of $8.5 million, or a basic and diluted GAAP loss per share of $0.71, for the same period the prior year.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the three months ended March 31, 2022; the sufficiency of the Company’s current cash, cash equivalents and marketable securities to fund its planned operations into the second quarter of 2023; our planned and ongoing clinical trials for the Company’s product candidates, including NEXI-001, NEXI-002 and NEXI-003; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical trials and preclinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to continue as a going concern absent access to sources of liquidity and the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on March 9, 2021, our Quarterly Report on Form 10-Q for the three months ended March 31, 2022 filed with the SEC on May 12, 2022, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
NEXIMMUNE, INC.
BALANCE SHEETS
March 31, 2022 | December 31, 2021 | ||||||
(unaudited) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 24,503,334 | $ | 30,326,352 | |||
Marketable securities | 40,506,415 | 51,491,942 | |||||
Restricted cash | 67,500 | 67,500 | |||||
Prepaid expenses and other current assets | 6,822,410 | 4,394,916 | |||||
Total current assets | 71,899,659 | 86,280,710 | |||||
Property and equipment, net | 4,475,089 | 4,427,307 | |||||
Operating lease right-of-use assets | 1,345,681 | — | |||||
Other non-current assets | 593,525 | 324,099 | |||||
Total assets | $ | 78,313,954 | $ | 91,032,116 | |||
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,007,994 | $ | 1,045,159 | |||
Accrued expenses | 4,497,425 | 6,170,709 | |||||
Operating lease liabilities, current | 585,916 | — | |||||
Total current liabilities | 7,091,335 | 7,215,868 | |||||
Operating lease liabilities, net of current portion | 829,440 | — | |||||
Deferred rent, net of current portion | — | 55,581 | |||||
Total liabilities | 7,920,775 | 7,271,449 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity | |||||||
Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,841,794 issued and outstanding as of March 31, 2022 and 22,828,904 shares issued and outstanding as of December 31, 2021 | 2,284 | 2,283 | |||||
Additional paid-in-capital | 213,177,933 | 211,498,827 | |||||
Accumulated other comprehensive income | (20,578 | ) | 3,012 | ||||
Accumulated deficit | (142,766,460 | ) | (127,743,455 | ) | |||
Total stockholders’ equity | 70,393,179 | 83,760,667 | |||||
Total liabilities, redeemable convertible preferred stock and stockholders’ equity | $ | 78,313,954 | $ | 91,032,116 |
NEXIMMUNE, INC.
STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended March 31, | |||||||
2022 | 2021 | ||||||
Revenue | $ | — | $ | — | |||
Operating expenses: | |||||||
Research and development | 10,448,843 | 6,012,608 | |||||
General and administrative | 4,604,679 | 4,057,592 | |||||
Total operating expenses | 15,053,522 | 10,070,200 | |||||
Loss from operations | (15,053,522 | ) | (10,070,200 | ) | |||
Other (expense) income: | |||||||
Interest income | 33,093 | 3,613 | |||||
Change in fair value of derivative liability | — | 2,424,877 | |||||
Gain on extinguishment of debt | — | ||||||
Interest expense | — | (904,119 | ) | ||||
Other expense | (2,576 | ) | (722 | ) | |||
Other income (expense) | 30,517 | 1,523,649 | |||||
Net Loss | $ | (15,023,005 | ) | $ | (8,546,551 | ) | |
Accumulated dividends on Redeemable Convertible Preferred Stock | — | (377,562 | ) | ||||
Net loss attributable to common stockholders | $ | (15,023,005 | ) | $ | (8,924,113 | ) | |
Basic and diluted net loss attributable to common stockholders per common share | $ | (0.66 | ) | $ | (0.71 | ) | |
Basic and diluted weighted-average number of common shares outstanding | 22,836,781 | 12,633,123 |
STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
Three Months Ended March 31, | |||||||
2022 | 2021 | ||||||
Net loss | $ | (15,023,005 | ) | $ | (8,546,551 | ) | |
Other comprehensive loss: | |||||||
Unrealized loss on available-for-sale marketable securities, net of tax | (23,590 | ) | — | ||||
Comprehensive loss | $ | (15,046,595 | ) | $ | (8,546,551 | ) |
Last Trade: | US$0.19 |
Daily Change: | -0.02 -9.52 |
Daily Volume: | 14,170 |
Market Cap: | US$264K |
February 06, 2024 February 02, 2024 October 19, 2023 August 10, 2023 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB